Esperance Pharmaceuticals Presents Results From Phase 1 Study of EP-100 in Advanced, Refractory ...
04:33 EDT 5 Jun 2012 | LaMerie
-- Phase 2 study of EP-100 plus paclitaxel in advanced ovarian cancer now enrolling patients --
Original Article: Esperance Pharmaceuticals Presents Results From Phase 1 Study of EP-100 in Advanced, Refractory ...
More From BioPortfolio on "Esperance Pharmaceuticals Presents Results From Phase 1 Study of EP-100 in Advanced, Refractory ..."
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
